188 related articles for article (PubMed ID: 30867376)
1. Rivaroxaban Suppresses the Progression of Ischemic Cardiomyopathy in a Murine Model of Diet-Induced Myocardial Infarction.
Liu J; Nishida M; Inui H; Chang J; Zhu Y; Kanno K; Matsuda H; Sairyo M; Okada T; Nakaoka H; Ohama T; Masuda D; Koseki M; Yamashita S; Sakata Y
J Atheroscler Thromb; 2019 Oct; 26(10):915-930. PubMed ID: 30867376
[TBL] [Abstract][Full Text] [Related]
2. Diet-induced occlusive coronary atherosclerosis, myocardial infarction, cardiac dysfunction, and premature death in scavenger receptor class B type I-deficient, hypomorphic apolipoprotein ER61 mice.
Zhang S; Picard MH; Vasile E; Zhu Y; Raffai RL; Weisgraber KH; Krieger M
Circulation; 2005 Jun; 111(25):3457-64. PubMed ID: 15967843
[TBL] [Abstract][Full Text] [Related]
3. The factor Xa inhibitor rivaroxaban reduces cardiac dysfunction in a mouse model of myocardial infarction.
Bode MF; Auriemma AC; Grover SP; Hisada Y; Rennie A; Bode WD; Vora R; Subramaniam S; Cooley B; Andrade-Gordon P; Antoniak S; Mackman N
Thromb Res; 2018 Jul; 167():128-134. PubMed ID: 29843086
[TBL] [Abstract][Full Text] [Related]
4. Rivaroxaban, a direct inhibitor of coagulation factor Xa, attenuates adverse cardiac remodeling in rats by regulating the PAR-2 and TGF-β1 signaling pathways.
Zhang Q; Zhang Z; Chen W; Zheng H; Si D; Zhang W
PeerJ; 2023; 11():e16097. PubMed ID: 37786576
[TBL] [Abstract][Full Text] [Related]
5. Scavenger Receptor Class B Type 1 Deletion Led to Coronary Atherosclerosis and Ischemic Heart Disease in Low-density Lipoprotein Receptor Knockout Mice on Modified Western-type Diet.
Liao J; Guo X; Wang M; Dong C; Gao M; Wang H; Kayoumu A; Shen Q; Wang Y; Wang F; Huang W; Liu G
J Atheroscler Thromb; 2017 Feb; 24(2):133-146. PubMed ID: 27373983
[TBL] [Abstract][Full Text] [Related]
6. Red Wine Grape Pomace Attenuates Atherosclerosis and Myocardial Damage and Increases Survival in Association with Improved Plasma Antioxidant Activity in a Murine Model of Lethal Ischemic Heart Disease.
Rivera K; Salas-Pérez F; Echeverría G; Urquiaga I; Dicenta S; Pérez D; de la Cerda P; González L; Andia ME; Uribe S; Tejos C; Martínez G; Busso D; Irarrázaval P; Rigotti A
Nutrients; 2019 Sep; 11(9):. PubMed ID: 31500172
[TBL] [Abstract][Full Text] [Related]
7. Targeting Coagulation Factor Xa Promotes Regression of Advanced Atherosclerosis in Apolipoprotein-E Deficient Mice.
Posthuma JJ; Posma JJN; van Oerle R; Leenders P; van Gorp RH; Jaminon AMG; Mackman N; Heitmeier S; Schurgers LJ; Ten Cate H; Spronk HMH
Sci Rep; 2019 Mar; 9(1):3909. PubMed ID: 30846818
[TBL] [Abstract][Full Text] [Related]
8. Cardioprotective Effects of Rivaroxaban on Cardiac Remodeling After Experimental Myocardial Infarction in Mice.
Nakanishi N; Kaikita K; Ishii M; Oimatsu Y; Mitsuse T; Ito M; Yamanaga K; Fujisue K; Kanazawa H; Sueta D; Takashio S; Arima Y; Araki S; Nakamura T; Sakamoto K; Suzuki S; Yamamoto E; Soejima H; Tsujita K
Circ Rep; 2020 Mar; 2(3):158-166. PubMed ID: 33693223
[No Abstract] [Full Text] [Related]
9. Warfarin, but not rivaroxaban, promotes the calcification of the aortic valve in ApoE-/- mice.
Rattazzi M; Faggin E; Bertacco E; Nardin C; Pagliani L; Plebani M; Cinetto F; Guidolin D; Puato M; Pauletto P
Cardiovasc Ther; 2018 Aug; 36(4):e12438. PubMed ID: 29847020
[TBL] [Abstract][Full Text] [Related]
10. Rivaroxaban attenuates cardiac hypertrophy by inhibiting protease-activated receptor-2 signaling in renin-overexpressing hypertensive mice.
Narita M; Hanada K; Kawamura Y; Ichikawa H; Sakai S; Yokono Y; Senoo M; Narita N; Shimada M; Osanai T; Okumura K; Tomita H
Hypertens Res; 2021 Oct; 44(10):1261-1273. PubMed ID: 34285375
[TBL] [Abstract][Full Text] [Related]
11. Rivaroxaban, a specific FXa inhibitor, improved endothelium-dependent relaxation of aortic segments in diabetic mice.
Pham PT; Fukuda D; Yagi S; Kusunose K; Yamada H; Soeki T; Shimabukuro M; Sata M
Sci Rep; 2019 Aug; 9(1):11206. PubMed ID: 31371788
[TBL] [Abstract][Full Text] [Related]
12. Rivaroxaban, a novel oral anticoagulant, attenuates atherosclerotic plaque progression and destabilization in ApoE-deficient mice.
Hara T; Fukuda D; Tanaka K; Higashikuni Y; Hirata Y; Nishimoto S; Yagi S; Yamada H; Soeki T; Wakatsuki T; Shimabukuro M; Sata M
Atherosclerosis; 2015 Oct; 242(2):639-46. PubMed ID: 25817329
[TBL] [Abstract][Full Text] [Related]
13. Protease-activated receptor 2 deficiency in hematopoietic lineage protects against myocardial infarction through attenuated inflammatory response and fibrosis.
Zuo P; Zhu Y; Li Y; Zuo Z; Sheng Z; Yan G; Ma G
Biochem Biophys Res Commun; 2020 May; 526(1):253-260. PubMed ID: 32204916
[TBL] [Abstract][Full Text] [Related]
14. Immunosuppression With FTY720 Reverses Cardiac Dysfunction in Hypomorphic ApoE Mice Deficient in SR-BI Expression That Survive Myocardial Infarction Caused by Coronary Atherosclerosis.
Luk FS; Kim RY; Li K; Ching D; Wong DK; Joshi SK; Imhof I; Honbo N; Hoover H; Zhu BQ; Lovett DH; Karliner JS; Raffai RL
J Cardiovasc Pharmacol; 2016 Jan; 67(1):47-56. PubMed ID: 26322923
[TBL] [Abstract][Full Text] [Related]
15. The effects of parathyroid hormone-related peptide on cardiac angiogenesis, apoptosis, and function in mice with myocardial infarction.
Zhang H; Gao Y; Wang Y; Yan Y; Yang Z; Miao D; Zhang D
J Cell Biochem; 2019 Sep; 120(9):14745-14755. PubMed ID: 30994964
[TBL] [Abstract][Full Text] [Related]
16. Preservation of Contractile Reserve and Diastolic Function by Inhibiting the NLRP3 Inflammasome with OLT1177
Aliaga J; Bonaventura A; Mezzaroma E; Dhakal Y; Mauro AG; Abbate A; Toldo S
Molecules; 2021 Jun; 26(12):. PubMed ID: 34207886
[TBL] [Abstract][Full Text] [Related]
17. Possible role of rivaroxaban in attenuating pressure-overload-induced atrial fibrosis and fibrillation.
Kondo H; Abe I; Fukui A; Saito S; Miyoshi M; Aoki K; Shinohara T; Teshima Y; Yufu K; Takahashi N
J Cardiol; 2018 Mar; 71(3):310-319. PubMed ID: 28993090
[TBL] [Abstract][Full Text] [Related]
18. Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice.
Braun A; Trigatti BL; Post MJ; Sato K; Simons M; Edelberg JM; Rosenberg RD; Schrenzel M; Krieger M
Circ Res; 2002 Feb; 90(3):270-6. PubMed ID: 11861414
[TBL] [Abstract][Full Text] [Related]
19. Factor Xa inhibition by rivaroxaban attenuates cardiac remodeling due to intermittent hypoxia.
Imano H; Kato R; Tanikawa S; Yoshimura F; Nomura A; Ijiri Y; Yamaguchi T; Izumi Y; Yoshiyama M; Hayashi T
J Pharmacol Sci; 2018 Jul; 137(3):274-282. PubMed ID: 30055890
[TBL] [Abstract][Full Text] [Related]
20. Establishment of a novel murine model of ischemic cardiomyopathy with multiple diffuse coronary lesions.
Nakaoka H; Nakagawa-Toyama Y; Nishida M; Okada T; Kawase R; Yamashita T; Yuasa-Kawase M; Nakatani K; Masuda D; Ohama T; Sonobe T; Shirai M; Komuro I; Yamashita S
PLoS One; 2013; 8(8):e70755. PubMed ID: 23950999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
